Vebreltinib combined with Furmonertinib

Phase 2Small molecule

PPeking University Cancer Hospital & Institute

Vebreltinib combined with Furmonertinib is one of 3 small molecule programs targeting MET Amplification. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MET AmplificationRecruiting

MET AmplificationPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in MET Amplification

#DrugCompanyPhaseTrials

Vebreltinib

AAvistone Biotechnology Co., Ltd.

Phase 2

1 2

PLB1004

AAvistone Biotechnology Co., Ltd.

Phase 2

1 3

Vebreltinib combined with Furmonertinib

PPeking University Cancer Hospital & Institute

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1/2Recruiting

MET Amplification

NCT07087223

Clinical

Trials by Indication[1]

MET Amplification1 trial

Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

Recruiting·PPeking University Cancer Hospital & Institute·Phase 1/2·NCT07087223·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vebreltinib combined with Furmonertinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vebreltinib combined with Furmonertinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vebreltinib combined with Furmonertinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University Cancer Hospital & Institute

Vebreltinib combined with Furmonertinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

MET Amplification1 trial

References

Drug Info

Quick Facts

Related News